I would like to comment on the interesting manuscript by Rogler et al.1 The authors highlight the rising incidence of Inflammatory Bowel Disease (IBD) in the developing world and express concern how such countries might finance the escalation of Biological therapy. They describe the barriers to access of these drugs, namely lack of infrastructure for financing and monitoring drug treatment. In their discussion, they explore how best to treat severe IBD in this context and argue that transfer of experience of anti-tumour necrosis factor agents from experts in the West to developing countries offers a means of increasing access to …